Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery

American Journal of Hematology

Volumn 86, Issue 4, 2011, Pages 351-352

  Ianotto, Jean Christophe ^a   Tempescul, Adrian ^a   Delepine, Pascal ^b   Guillerm, Gaelle ^a   Hardy, Elisabeth ^b   Eveillard, Jean Richard ^a   Berthou, Christian ^a  

^a CHU MORVAN   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; MELPHALAN;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITALIZATION COST; HUMAN; LEUKOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; PARENTERAL NUTRITION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 79953067394     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21991     Document Type: Article

References (10)

1. McQuaker IG, Hunter AE, Pacey S, et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
2. Lee SM, Radford JA, Dobson L, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294-1299.
3. Valteau-Couanet D, Faucher C, Auperin A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: Results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005; 36: 547-552.
4. Pagliuca A, Carrington PA, Pettengel R, et al. Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol 2003; 123: 22-33.
5. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
6. Apperley J, Carreras E, Gluckman E, et al. Haematopoietic stem cell transplantation. The EBMT Handbook 2008 Revised Version. pp 171-173.
7. Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965-969.
8. Bolwell BJ, Pohlman B, Andresen S, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369-373.
9. Trivedi M, Martinez S, Corringham S, et al. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 2009; 43: 895-908.
10. Rifkin R, Spitzer G, Orloff G, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 186-191.